Breaking News

Financial Report: Roche YTD11

Foreign exchange hurts results

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

YTD Revenues: 31.5 billion (-13%) Comments: Group sales were down -12%, excluding Tamiflu. Pharmaceutical sales were 24.4 billion (-14%). Herceptin sales were up +8% and MabThera/Rituxan, up +7%. Lucentis sales were up 26%. Actemra sales jumped +86%. Professional Diagnostics business revenues were up 9%. Foreign exchange negatively impacted results by -13% due to appreciation of the Swiss franc. All numbers reported in CHF...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters